Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Zimlovisertib MR Formulation in Healthy Adults
NCT02609139Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of zimlovisertib in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) (6 arms), sponsored by Pfizer. Primary endpoint: Plasma pharmacokinetic parameters of PF-06650833 at Day 14. Started Nov 2015; status: completed.
02
Drugs
zimlovisertib
03
Conditions
rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02609139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02609139.